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Empiric guideline-recommended weight-based
vancomycin dosing and nephrotoxicity rates in
patients with methicillin-resistant Staphylococcus
aureus bacteremia: a retrospective cohort study
Ronald G Hall II1,2*, Kathleen A Hazlewood1,7, Sara D Brouse1,8, Christopher A Giuliano3,9, Krystal K Haase3,
Chistopher R Frei4, Nicolas A Forcade4,10, Todd Bell5, Roger J Bedimo6 and Carlos A Alvarez1,2
Abstract
Background: Previous studies have established a correlation between vancomycin troughs and nephrotoxicity.
However, data are currently lacking regarding the effect of guideline-recommended weight-based dosing on
nephrotoxicity in methicillin-resistant Staphylococcus aureus bacteremia (MRSAB).
Methods: Adults who were at least 18 years of age with methicillin-resistant Staphylococcus aureus bacteremia and
received of empiric vancomycin therapy for at least 48 hours (01/07/2002 and 30/06/2008) were included in this
multicenter, retrospective cohort study. The association between guideline-recommended, weight-based
vancomycin dosing (at least 15 mg/kg/dose) and nephrotoxicity (increase in serum creatinine (SCr) by more than
0.5 mg/dl or at least a 50% increase from baseline on at least two consecutive laboratory tests) was evaluated.
Potential independent associations were evaluated using a multivariable general linear mixed-effect model.
Results: Overall, 23% of patients developed nephrotoxicity. Thirty-four percent of the 337 patients who met study
criteria received weight-based dosing. The cohort was composed of 69% males with a median age of 55 years. The
most common sources of MRSAB included skin/soft tissue (32%), catheter-related bloodstream bacteremia (20%),
pulmonary (18%). Eighty-six percent of patients received twice daily dosing. Similar rates of nephrotoxicity were
observed regardless of the receipt of guideline-recommended dosing (22% vs. 24%, OR 0.91 [95% CI 0.53-1.56]). This
finding was confirmed in the multivariable analysis (OR 1.52 [95% CI 0.75-3.08]). Independent predictors of
nephrotoxicity were (OR, 95% CI) vancomycin duration of greater than 15 days (3.36, 1.79-6.34), weight over 100 kg
(2.74, 1.27-5.91), Pitt bacteremia score of 4 or greater (2.73, 1.29-5.79), vancomycin trough higher than 20 mcg/ml
(2.36, 1.07-5.20), and age over 52 years (2.10, 1.08-4.08).
Conclusions: Over one out of five patients in this study developed nephrotoxicity while receiving vancomycin for
MRSAB. The receipt of guideline-recommended, weight-based vancomycin was not an independent risk factor for
the development of nephrotoxicity.
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Background
Decreased vancomycin efficacy has been reported by
several investigators for methicillin-resistant Staphyloco-
cus aureus (MRSA) isolates with a vancomycin MIC of 1
μg/ml or higher [1-3]. This has been accompanied by a
trend of increased vancomycin minimum inhibitory con-
centrations (MIC) in MRSA isolates [4]. Experts in the
field have responded in two ways. First, the Clinical and
Laboratory Standards Institute lowered the susceptibility
breakpoint for vancomycin versus S. aureus [5]. Second,
several influential organizations endorsed a consensus
review recommending higher vancomycin trough con-
centrations [6]. Weight-based dosing was recommended
to achieve these new target vancomycin trough concen-
trations. The impact of these two changes on the safety
profile of vancomycin is unknown. Recent studies sug-
gest increased vancomycin trough concentrations are a
risk factor for increased rates of nephrotoxicity [1,7-10].
However, no studies have yet evaluated the effect of
guideline-recommended, weight-based vancomycin dos-
ing on nephrotoxicity. We performed a multi-center
retrospective cohort study to assess the risk of nephro-
toxicity associated with guideline-recommended, weight-
based vancomycin dosing.
Methods
Design
We conducted a multi-center, retrospective cohort study
at three hospitals between July 2002 and June 2008. This
retrospective cohort evaluated the association between the
receipt of weight-based vancomycin dosing as recom-
mended in the 2009 guideline and the development of
nephrotoxicity in patients with MRSA bacteremia [6]. The
development of nephrotoxicity during vancomycin ther-
apy was the primary outcome of interest. All data were
collected from the patient’s medical record at each study
institution. The results of our evaluation of guideline-
recommended, weight-based dosing and mortality can be
found elsewhere [11].
Setting
The three study hospitals were a 400 bed tertiary hos-
pital, a 350 bed Veteran Affairs hospital, and a 600 bed
university hospital. The requirement for informed con-
sent was waived by each of the institutional review
boards (IRBs) that approved the study (North Texas
Veterans Health Care System, Texas Tech University
Health Sciences Center, and University of Texas Health
Science Center, San Antonio) due to the retrospective
nature of the study and being deemed as minimal risk.
Patients
All adults (18 years or older) admitted with MRSA
bacteremia (identified by microbiological records) who
received parenteral vancomycin for at least 48 hours were
evaluated for study inclusion. Patients were excluded if at
the time of the first vancomycin dose they were pregnant,
had moderate-to-severe renal dysfunction (defined as a
creatinine clearance (CrCl) ≤ 30 ml/min or receipt of
dialysis), received vancomycin within the same hospital
stay, or had a culture-proven MRSA infection within six
months [12]. Patients with a CrCl ≤ 30 ml/min were
excluded because these patients were considered more
likely to require a dosing frequency adjustment to less
than once daily dosing and the measure of vancomycin
dosing intensity used was mg/kg/day. Prior MRSA infec-
tions were excluded due to the likely prior receipt of
vancomycin.
Definitions
The study team agreed upon the following definitions
while designing this study. Nephrotoxicity was defined
as an increase in serum creatinine (SCr) by greater than
a 0.5 mg/dl or 50% increase from baseline on at least
two consecutive laboratory tests during the period from
initiation of vancomycin to completion of therapy [6].
We compared the nephrotoxicity rates among patients
treated with guideline-recommended vancomycin doses
(at least 30 mg/kg/day; at least 15 mg/kg/day for CrCl
30-50 ml/min) to those treated with lower vancomycin
doses (less than 30 mg/kg/day; less than 15 mg/kg/day
for CrCl 30-50 ml/min). Vancomycin trough concentra-
tions were determined by the assay used for routine
patient care at each institution. All concentrations
labeled as “trough” were utilized. Only the first/initial
vancomycin trough concentration was utilized in the
analysis. All study hospitals did not have a mandatory
therapeutic drug monitoring service and therefore
vancomycin trough concentrations were only obtained
as clinically indicated by the prescribing physician. Pitt
bacteremia score and Charlson comorbidity index were
used to quantify severity of illness and comorbid condi-
tions. Both of these indices have been described in detail
elsewhere [13-15].
Statistical analysis
All analyses were performed using SAS 9.2 (Cary, North
Carolina) and RTREE (Available at: http://c2s2.yale.edu/
software/rtree/). It was determined that seven to eight
variables would likely be evaluated in the multivariable
model. In order to prevent overfitting, a total of 70-80
events would be required. Assuming a nephrotoxicity
rate of 25% based on prior literature, 280-320 patients
would be required for the multivariable analysis [1,7].
Candidate variables selected for consideration in the
multivariable model were identified a priori. Univariable
associations were explored using either Chi-square or
Fisher’s Exact tests. Dichotomization of continuous
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variables was achieved by recursive partitioning to
determine significant cut-points [16]. A Pitt bacteremia
score ≥ 4 was used based on previous literature [17]. A
vancomycin trough greater than 20 mcg/ml was based
on previous observations of increased rates of nephro-
toxicity compared with troughs of 15-20 mcg/ml [10].
The univariable analysis included the following candidate
variables: receipt of guideline-recommended, weight-based
vancomycin dosing, vancomycin trough greater than 20
mcg/ml, duration of vancomycin treatment greater than
15 days, gender, age greater than 52 years, weight greater
than 100 kg, Pitt bacteremia score of 4 or higher, intensive
care unit (ICU) residence, use of concomitant nephrotox-
ins (e.g. contrast dye, aminoglycosides, vasopressors),
baseline serum creatinine, and Charlson comorbidity
index score of 5 or higher.
Consideration for inclusion in the multivariable model
was based on our conceptual model as well as significant
associations observed in the univariable analysis (p<0.1).
Independent predictors of nephrotoxicity were deter-
mined using a multivariable generalized linear mixed-
effect model. Hospital site was treated as a random
effect whereas other covariates were treated as fixed
effects. A p value of <0.05 was considered statistically
significant for the multivariable model. The analysis also
included an extensive evaluation of effect measure modi-
fication and biologic interaction.
Results
Of the 798 patients with MRSA bacteremia, 337
were included in the cohort (Hospital A = 156, Hospital
B = 100, Hospital C = 81). Reasons for patient exclusion
were not collected by the automated screening process.
The baseline characteristics of the cohort are shown in
Table 1. The cohort was predominantly male (79.2%) and
was comprised of Caucasians (65%), African-Americans
(14%), and Hispanics (17%). Data regarding race/ethnicity
were missing for 5 patients and documented as other in
seven patients. Vancomycin was dosed according to 2009
guidelines in 33.6% percent of patients. Patients weighing
≥ 100 kg received similar doses per day to those weighing
< 100 kg (1941 mg vs. 1919 mg, p = 0.72). Patients receiv-
ing guideline-recommended, weight-based vancomycin
dosing had a median daily dose of 32.0 mg/kg/day (inter-
quartile range 29.0, 36.0), while those receiving lower doses
received 21.3 mg/kg/day (interquartile range 17.0, 26.0)
(p < 0.001). As expected, vancomycin trough concentra-
tions were higher in patients receiving guideline-
recommended, weight-based dosing (12.3 mcg/ml, IQR
8.3, 17.5) compared to patients who received lower doses
(10.1 mcg/ml, IQR 7.1, 14.9), p = 0.03. The most common
dosing frequencies administered were once (11.3%) or
twice daily (86.3%). Other dosing frequencies included
thrice daily (2.1%) or every other day (0.3%). The most
common sources of infection for patients receiving
weight-based vancomycin dosing according to the 2009
guideline were bloodstream catheter-related (16.6%),
central nervous system (0.4%), gastrointestinal (0.9%), gen-
itourinary (6.7%), osteomyelitis (1.3%), pulmonary (19.3%),
skin/soft tissue (37.7%), and other (0.5%). The source of
infection was undocumented for 16.6% of patients. For
patients receiving lower doses, the sources of infection
were bloodstream catheter-related (27.4%), genitourinary
(10.6%), osteomyelitis (0.9%), pulmonary (15%), skin/soft
tissue (20.4%). The source of infection was undocumented
in 25.7% of patients receiving lower dosing.
Table 1 Baseline characteristics of the cohortA
Characteristic Guideline-recommended dosing (n = 113)* Lower dosing (n = 223)+ p-value
Male gender (%) 76% 81% 0.97
Age (years) 57 (46, 71) 54 (44, 63) 0.03
Height (cm) 172 (163, 178) 175 (168, 183) <0.001
Weight (kg) 63 (57, 68) 88 (75, 104) <0.001
Serum creatinine (mg/dl) 0.9 (0.7, 1.3) 0.9 (0.7, 1.2) 0.70
Creatinine clearance (ml/min) 71 (47, 104) 86 (66, 124) <0.001
Charlson comorbidity index > 5 20% 13% 0.06
Length of hospital stay (days) 17 (9, 37) 18 (9, 32) 0.60
Intensive care unit resident 41% 41% 0.99
Pitt bacteremia ≥ 4 21% 22% 0.80
Concomitant nephrotoxin 50% 49% 0.85
Nephrotoxicity 22% 24% 0.74
Initial Vancomycin Dose (mg/kg/day) 32 (29, 36) 21 (17, 26) <0.001
A = Results are presented as median (interquartile range) unless otherwise noted.
* = Vancomycin ≥ 30 mg/kg/day, ≥ 15 mg/kg/day for creatinine clearance of 30-50 ml/min.
+ = Vancomycin < 30 mg/kg/day, < 15 mg/kg/day for creatinine clearance of 30-50 ml/min.
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Nephrotoxicity occurred in 78 patients (23%), occur-
ring in 56%, 11%, and 33% of patients at Hospitals A, B,
and C, respectively. The median (interquartile range) in-
crease from baseline to peak serum creatinine was 0.0
mg/dL (0.0, 0.2) for patients who did not develop
nephrotoxicity versus 1.0 mg/dL (0.6, 2.1) for patients
who developed nephrotoxicity. Fifteen percent of
patients had a vancomycin trough concentration greater
than 20 mcg/ml. Concurrent nephrotoxins included con-
trast dye (34%), aminoglycosides (19%), and vasopressors
(12%). Concomitant antimicrobials active against MRSA
were used in 23% of patients.
In the univariable analysis (Table 2), nephrotoxicity
was similar between patients that received guideline-
recommended, weight-based vancomycin dosing versus
lower dosing (22% vs. 24%). Factors associated with
increased risk for nephrotoxicity included duration of
vancomycin treatment greater than 15 days, weight
greater than 100 kg, Pitt bacteremia score of 4 or higher,
vancomycin trough greater than 20 mcg/ml, age greater
than 52 years, ICU residence, and concomitant nephro-
toxin. In the multivariable analysis there was not a statisti-
cally significant association between vancomycin dosing
and nephrotoxicity (Table 3). Independent predictors of
nephrotoxicity in the multivariable model were duration
of vancomycin treatment greater than 15 days, weight
greater than 100 kg, Pitt bacteremia score of 4 or higher,
vancomycin trough greater than 20 mcg/ml, and age
greater than 52 years.
Discussion
We did not observe a statistically significant relationship
between the receipt of guideline-recommended, weight-
based dosing of vancomycin and the development of
nephrotoxicity in patients in our cohort. This finding is
clinically important because weight-based vancomycin
dosing is now recommended by the vancomycin guide-
lines [6].
The impact of vancomycin on the development of
nephrotoxicity has been debated for decades. Multiple
prospective clinical trials suggest that traditional vanco-
mycin doses (1 gram IV every 12 hours) cause nephro-
toxicity 5% of the time, or less, when concomitant
nephrotoxins are not used [18-21]. A 7-35% rate of
nephrotoxicity was reported with the concomitant use of
nephrotoxins [22,23].
The controversy surrounding vancomycin-associated
nephrotoxicity has resurfaced in parallel with the
increased utilization of higher vancomycin doses to
achieve higher target trough concentrations in response to
rising vancomycin MIC values. The nephrotoxicity rate in
our study (23%) is consistent with recent data utilizing a
standard definition of nephrotoxicity (11-42%) [1,7-10].
Our study also agreed with other studies that have
identified an association between vancomycin trough
concentrations and nephrotoxicity [1,7-10]. These stud-
ies, and our own, are unable to determine whether this
association is causative in nature. Our observation of an
association between duration of vancomycin treatment
and nephrotoxicity is also consistent with previous work
[1,7,9]. Whether vancomycin duration is a causative fac-
tor in nephrotoxicity is also unclear.
The factors significantly associated with the develop-
ment of nephrotoxicity in our study are clinically rea-
sonable. We found that a Pitt bacteremia score of 4 or
greater was predictive of nephrotoxicity in our study.
This is consistent with other studies that have observed
a significant association between nephrotoxicity and
ICU residence upon antibiotic initiation or increased
APACHE II scores [7,8,24]. We observed that greater
patient weight was significantly associated with the de-
velopment of nephrotoxicity, which is also consistent
with previous investigations [8,24].
The application of our study is limited by its retro-
spective nature and the potential lack of external validity
Table 2 Univariable analysis of risk factors for
nephrotoxicity
Variable Odds
ratio
95% confidence
interval
Guideline-recommended vancomycin dosing 0.91 0.53-1.56
Vancomycin duration > 15 days 3.65 2.16-6.17
Weight greater than 100 kilograms 2.08 1.18-3.67
Pitt Bacteremia Score of four or greater 3.80 2.17-6.63
Vancomycin trough greater than 20 mcg/ml 2.51 1.28-4.92
Age greater than 52 years 2.40 1.38-4.15
Intensive care unit resident 3.64 2.15-6.18
Concomitant nephrotoxin 2.08 1.24-3.49
Male gender 1.04 0.56-1.57
Charlson comorbidity index 5 or greater 1.14 0.57-2.27
Baseline serum creatinine greater than
1.0 mg/dL
0.94 0.56-1.57
Table 3 Multivariable analysis of independent risk factors
for nephrotoxicity
Variable Odds
ratio
95% confidence
interval
Guideline-Recommended Vancomycin Dosing 1.52 0.75-3.08
Vancomycin duration greater than 15 days 3.36 1.79-6.34
Weight greater than 100 kilograms 2.74 1.27-5.91
Pitt Bacteremia Score of four or greater 2.73 1.29-5.79
Vancomycin trough greater than 20 mcg/ml 2.36 1.07-5.20
Age greater than 52 years 2.10 1.08-4.08
Intensive care unit residence 1.90 0.95-3.80
Concomitant nephrotoxin 1.64 0.87-3.11
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in patients being treated with vancomycin for conditions
other than MRSA bacteremia. The lack of information
regarding reasons for exclusion may also limit how other
institutions are able to use these findings for their pa-
tient population. Retrospective studies may have differ-
ences between the comparison groups in regards to
measured and unmeasured confounders. To address po-
tential confounding, a stratified analysis was conducted
on variables considered to potentially affect the primary
outcome. Biologically plausible factors that demon-
strated confounding were included in the multivariable
model. A multivariable mixed-effects model using hos-
pital site as the random effect was utilized to minimize
the impact of the differences in measured confounders
as well as the risk of clustering. One major difference
between the institutions is the much longer length of
stay at Hosptial A due to two long-term care wings in
the facility compared to none for the Hospitals B and C.
Therefore, the higher nephrotoxicity rate at Hospital A
may be in part due to an observation bias due to
patients on vancomycin remaining in the hospital longer
than patients at the other institutions.
The fact that we did not observe an association be-
tween concomitant nephrotoxins and nephrotoxicity
may have been due to the lack of recording the dose and
duration of concomitatnt nephrotoxin use. Our results
may have also been subject to a selection bias since
patients weighing greater than 70 kilograms were less
likely to receive weight-based vancomycin dosing as
recommended by the 2009 guideline. This selection bias
could have reduced our ability to detect guideline-
recommended, weight-based dosing as an independent
risk factor for nephrotoxicity. The utilization of all
vancomycin concentrations labeled as “troughs” could
have biased our results. The potential for each institu-
tion to use different vancomycin assays could have also
biased our results. However, our study found that vanco-
mycin troughs greater than 20 mcg/ml is associated with
nephrotoxicity mirroring those of previous studies. This
lack of effect is common for most non-differential mis-
classification biases. If any effect were to occur to this
bias, it would have been to lessen the ability to deter-
mine that vancomycin trough concentrations are a risk
factor for nephrotoxicity. The exclusion of patients with
missing vancomycin trough concentrations from the
multivariable model may have also biased the results.
This exclusion may have created a selection bias that
decreased the ability to detect severity of illness or length
of vancomycin therapy as patients without therapeutic
drug monitoring tend to be less severely ill patients who
do not require long durations of therapy. The fact that
both of these characteristics remained independent pre-
dictors of nephrotoxicity in spite of this selection bias
reinforces the strength of these associations. Last, our
study evaluated dosing practices prior to the publication
of the 2009 guidelines. However, this standard measure
created two distinct groups supported by the 2009 guide-
line regardless of how often weight-based vancomycin was
utilized during the study period.
Furthermore, the implications of loading doses and
therapeutic drug monitoring programs on nephrotoxicity
need further evaluation since none of our institutions
utilized loading doses or formal therapeutic drug monitor-
ing services (e.g. automatic pharmacy consultation for
vancomycin management). Each study institution employs
clinical pharmacists who monitor vancomycin trough
concentrations and provide recommendations for the
physician to clinically evaluate.
Conclusions
In this multi-center study, more than one in five patients
developed nephrotoxicity. We did not observe a significant
relationship between weight-based guideline-recommended
dosing and nephrotoxicity. If this finding is confirmed by
others, clinicians should be able to utilize weight-based,
guideline-recommended dosing. Careful management of
patients with MRSAB is needed to avoid vancomycin
trough concentrations associated with nephrotoxicity.
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